

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Vigonvita Life Sciences Co., Ltd.**

**蘇州旺山旺水生物醫藥股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2630)**

## **SUPPLEMENTAL ANNOUNCEMENT ON THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2025**

Reference is made to the annual report of Vigonvita Life Sciences Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended December 31, 2025 published on April 30, 2026 (the “**Annual Report**”) in relation to the confirmation of the Company’s independent auditor relating to the continuing connected transaction pursuant to the Rule 14A.56 of the Listing Rules. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Annual Report.

The Board (the “**Board**”) of the Directors (“**Director(s)**”) of the Company hereby announces that, a letter from the independent auditor, Deloitte Touche Tohmatsu, on May 22, 2026, is received by the Board which has confirmed with the Board that nothing has come to their attention that causes them to believe that the continuing connected transactions relating to the purchase of API and ancillary services by the Group as disclosed in the Annual Report:

- (i) were not approved by the Board;
- (ii) were not, in all material respects, conducted in accordance with the terms of the relevant agreements governing such transactions; and
- (iii) exceeded the relevant annual caps disclosed in the Prospectus of the Company in respect of the aggregate value of each transaction.

The Board further confirms that none of the continuing connected transactions set out in the Annual Report was related to the provision of the goods or services by the Group. This announcement is a supplement to, and should be read in conjunction with, the Annual Report.

The supplemental information contained in this announcement does not affect other information contained in the Annual Report. Save as disclosed above, all other information in the Annual Report remains unchanged.

By order of the Board  
**Vigonvita Life Sciences Co., Ltd.**  
**Dr. Tian Guanghui**  
*Chairman of the Board, Executive Director,  
Chief Executive Officer and General Manager*

Hong Kong, May 22, 2026

*As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.*